Marinus Story

<div class='circular--portrait' style='background:#FF0000;color: #F8F8FF;font-size:4em;'>MP</div>
MRNS -- USA Stock  

USD 14.36  0.49  3.30%

As many baby boomers are still indifferent towards healthcare space, it makes sense to sum up Marinus Pharma CS. We will evaluate why we are still confident in anticipation of a recovery. Is the firm valuation sustainable? Here I will cover a perspective on valuation of Marinus to give you a better outlook on taking a position in this stock.
Published over a month ago
View all stories for Marinus Pharma | View All Stories
Is Marinus Pharma (NASDAQ:MRNS) ready for a correction?
This firm currently holds 3.16 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest Marinus Pharma is not taking enough advantage from borrowing.
Our investment recommendation tool can cross-verify current analyst consensus on Marinus Pharma CS and to analyze the entity potential to grow in the current economic cycle.
We determine the current worth of Marinus Pharma CS using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Marinus Pharma CS based exclusively on its fundamental and basic technical indicators. By analyzing Marinus Pharma's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Marinus Pharma's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Marinus Pharma. We calculate exposure to Marinus Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Marinus Pharma's related companies.

Marinus Pharma CS Investment Alerts

Marinus investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Marinus Pharma CS performance across your portfolios.Please check all investment alerts for Marinus

Marinus Pharma Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Marinus value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Marinus Pharma competition to find correlations between indicators driving the intrinsic value of Marinus.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Marinus Pharma, but it might be worth checking our own buy vs. sell analysis

Breaking it down a bit more

The company reported the previous year's revenue of 171 K. Net Loss for the year was (74.3 M) with profit before overhead, payroll, taxes, and interest of 89.47 K.
 2020 2021 (projected)
Interest Expense182.85 K253.21 K
Gross Profit90 K89.47 K

Margins Breakdown

Marinus profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Marinus Pharma itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Marinus Pharma profit margins.
EBITDA Margin(10.43)
Gross Margin0.89
Profit Margin(34.91)


Marinus Pharma Earnings Before Interest Taxes and Depreciation Amortization USD is relatively stable at the moment. Also, Marinus Pharma Average Assets is increasing over the last 8 years.

Are Marinus Pharma technical ratios showing a correction?

The value at risk is down to -5.19 as of today. Marinus Pharma CS shows above-average downside volatility for the selected time horizon. We advise investors to inspect Marinus Pharma CS further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Marinus Pharma future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Marinus Pharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Marinus Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Take On Marinus Pharma

While some companies within the biotechnology industry are still a little expensive, even after the recent corrections, Marinus Pharma may offer a potential longer-term growth to retail investors. The bottom line, as of the 9th of March 2021, our up-to-date 30 days buy-hold-sell advice on the enterprise is Hold. We believe Marinus Pharma is undervalued with below average odds of financial distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Marinus Pharma CS. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com